- Home
- XERS vs ELVN Comparison
XERS vs ELVN Comparison
Compare XERS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | ELVN |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XERS | ELVN |
|---|---|---|
| Price | $6.72 | $21.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.00 | ★ $41.20 |
| AVG Volume (30 Days) | ★ 2.8M | 503.0K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $266,137,000.00 | N/A |
| Revenue This Year | $43.89 | N/A |
| Revenue Next Year | $20.40 | $20.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.05 | N/A |
| 52 Week Low | $3.14 | $13.30 |
| 52 Week High | $10.08 | $25.96 |
Technical Indicators
Market Signals| Indicator | XERS | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 53.34 |
| Support Level | $6.47 | $19.58 |
| Resistance Level | $7.24 | $22.14 |
| Average True Range (ATR) | 0.29 | 1.31 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 24.81 | 52.07 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.